FOSTER CITY, Calif.--(BUSINESS WIRE)--April 25, 2006--Gilead Sciences, Inc. (Nasdaq:GILD - News) today announced the closing of its sale of $650 million principal amount of Convertible Senior Notes due 2011 and $650 million principal amount of Convertible Senior Notes due 2013 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of Convertible Senior Notes sold reflects the full exercise by the initial purchasers of their option to purchase additional Convertible Senior Notes to cover over-allotments. The net proceeds from this offering were approximately $1.28 billion, after deducting estimated discounts, commissions and expenses.
